Mechanical ventilation during extracorporeal membrane oxygenation

1Over the past decade, the use of two distinct modalities of extracorporeal membrane oxygenation (ECMO) for respiratory and cardiac support in adults has increased. Venovenous (VV)-ECMO may be initiated as a treatment strategy for patients with severe acute respiratory failure, including adult respiratory distress syndrome (ARDS), as a salvage therapy for patients with profound gas-exchange abnormalities despite positive-pressure ventilation. Additionally, partial extracorporeal support systems have been suggested for less severe respiratory failure as an adjunct to invasive mechanical ventilation (MV) for patients who have excessively high inspiratory airway pressures or who are unable to tolerate volume-limited and pressure-limited strategies. These devices predominately remove carbon dioxide (CO2) from the blood and provide limited oxygenation. Such systems are often classified as extracorporeal carbon dioxide removal (ECCO2R) systems and cannot provide complete respiratory support. VV-ECMO and ECCO2R may now be considered management options for chronic end-stage respiratory failure where MV is contraindicated or undesirable; for example, as a bridge to lung transplantation in patients with cystic fibrosis who need to perform airway clearance techniques for sputum retention. ECCO2R has also been described for chronic obstructive pulmonary disease patients with prolonged weaning of invasive MV. Venoarterial (VA)-ECMO is a rapidly deployable treatment option for temporary circulatory assistance in patients with cardiogenic shock or refractory cardiac arrest secondary to a large number of acute and chronic cardiac illnesses.

2MV management during VV-ECMO and VA-ECMO has received scant attention to date despite high-level evidence to support low-tidal-volume ventilation strategies to improve survival. The design of randomized controlled trials of ECMO in ARDS did not use standardized protective ventilation in the interventional arm or in the control arm, which could have jeopardized the success of the ECMO treatment in these trials. MV settings may have important implications in both modes of ECMO (that is, VV-ECMO and VA-ECMO). Patients with the most severe forms of lung injury are likely to be particularly susceptible to ventilator-associated lung injury. Limiting stress and strain with a volume-limited and pressure-limited protective ventilation strategy beyond that recommended for patients with ARDS could provide additional benefit during ECMO support. For patients with severe cardiac failure supported with VA-ECMO, pulmonary artery blood flow may be severely reduced and the maintenance of normal alveolar ventilation might lead to severe over-ventilation of the lungs. Positive airway pressure settings will also affect right and left ventricular load in both VV-ECMO and VA-ECMO.

3Brief guidelines for the use of ECMO and expert points of views have been published, mostly during the recent influenza A(H1N1) pandemic. These publications are based on clinician preference, experience of centers with high case volumes, previous randomized trials and local resource availability.

4While there are extensive reviews on ECMO management, there is a significant knowledge gap in understanding the benefits and risks of MV during ECMO. Unlike previous reviews on ECMO, this review will focus on MV during ECMO. The purpose is to highlight the interactions between MV, ECMO and the pathophysiology of severe acute respiratory and cardiac failure. A second purpose is to provide evidence of the risks associated with MV during ECMO. Additionally, this review will summarize current guidelines, describe new strategies advocated for MV, provide evidence-based criteria that can be used for MV during ECMO and discuss what future studies are needed to address the evidence gap in this area.

5The extent of nonpulmonary gas exchange required during ECMO is directly related to the limitation of pulmonary gas exchange. The amount of oxygen supplied to the patient by the ECMO circuit is limited by the maximal oxygen delivery of the membrane (that is, membrane outlet–inlet oxygen content). The current generation of ECMO membranes can deliver up to 450 ml oxygen/minute. Actual patient oxygen delivery from an ECMO circuit is affected by the rate of circuit blood flow, the hemoglobin concentration and the oxyhemoglobin saturation of the venous blood (partly reflecting the level of recirculation). Of note, with VV-ECMO the circuit blood flow is related to both the inflow cannula diameter and the cardiac output. The CO2 content in blood is higher than the oxygen content, and is rapidly diffusible. CO2 transfer provided by current membranes may exceed 450 ml/minute depending on the ratio of gas to blood flow in the membrane and the CO2 partial pressure. Higher sweep gas flow and higher CO2 partial pressure in the oxygenator blood result in greater CO2 clearance. CO2 removal is therefore easily controlled with sweep gas flow settings.

6MV can activate inflammation and worsen the pulmonary damage of the underlying disease, leading to ventilator-induced lung injury (VILI). Three possible causal mechanisms of VILI may be modifiable with the use of ECMO.

7First is the alveolar strain, which represents the amount of aerated lung receiving ventilation. In 2000, the ARDS Network published a multicenter randomized clinical trial where a strategy aimed at maintaining plateau pressure ≤30 cmH2O with an initial tidal volume of ≈ 6 ml/kg predicted body weight (PBW) was compared with traditional ventilation treatment that involved an initial tidal volume of ≈ 12 ml/kg PBW. The protective ventilation, which minimizes the alveolar strain physiological concept, was associated with a decreased mortality of 22%. Patients at many centers who have received ECMO for severe ARDS have a very low arterial partial pressure of oxygen/fraction of inspired oxygen ratio (≈50 mmHg) and a very high acute injury score. In addition, these patients have a very small area of normally aerated alveoli located in the nondependent lung, a large consolidated or nonaerated region located in the dependent lung along the vertical axis and frequent infiltration of all of the four lung’s quadrants on chest radiographs. As the aerated compartment receives the largest part of the tidal volume, these severely unwell patients with a large amount of collapsed lung may be exposed to VILI despite low-tidal-volume ventilation strategies. Limitation of the alveolar strain is a major concern of patients with ARDS receiving MV during ECMO.

8A second mechanism of VILI is due to repeated intra-tidal alveolar opening and closing (atelectrauma), defined as the amount of collapsed lung tissue that is re-opened during inspiration and re-collapsed during expiration. The challenge is to find the right ventilator settings to avoid intra-tidal alveolar opening and closing while limiting the risk of alveolar overdistension or strain. Combining a low tidal volume with high levels of positive end-expiratory pressures (PEEP) appears to be important. Caironi and colleagues showed similar alveolar strain after application of 15 cmH2O PEEP in two distinct groups of 34 ARDS/acute lung injury patients (that is, higher vs. lower percentage of potentially recruitable lung groups), suggesting that the beneficial impact of reducing intra-tidal alveolar opening and closing by increasing PEEP prevailed over the effects of increasing alveolar strain. Of note, despite improving oxygenation and reducing the duration of MV, a strategy for setting PEEP aimed at increasing alveolar recruitment while limiting hyperinflation did not significantly reduce mortality in ARDS.

9Finally, oxygen lung toxicity from a high fraction of inspired oxygen in lung areas with a low ventilation–perfusion ratio might alone cause reabsorption atelectasis. Such areas are frequent in ARDS, and Aboab and colleagues showed in mechanically ventilated patients with acute lung injury that the breathing of pure oxygen leads to derecruitment, which is prevented by high PEEP. The challenge of MV settings with ECMO, particularly when lung function is severely impaired, is to minimize these pitfalls.

10Patients with cardiac failure receiving VA-ECMO often have abnormal lung function that may be associated with ARDS. Considerations from the previous section may also apply to this group. However, the major cardiovascular effect associated with PEEP is reduction in cardiac output. Although the effect of PEEP on cardiac output is complex, the decrease is caused predominantly by decreasing the right ventricular preload and direct heart–lung interaction. By increasing the intrathoracic pressure, PEEP can increase pulmonary vascular resistance, which may cause right ventricular overload and reduced left ventricular compliance. Patients who have received VA-ECMO with predominately right ventricular failure can be adversely affected by high PEEP. Conversely, patients with predominately left ventricular failure supported with VA-ECMO may develop pulmonary edema despite adequate systemic support and often benefit from the application of high PEEP.

11Additionally, VA-ECMO may dramatically reduce pulmonary blood flow as a result of pulmonary shunting. If normal lung ventilation is maintained in this setting, severe local alkalosis might result. To date, this potential deleterious effect has not been widely described and clinical consequences are still unknown. However, some authors have suggested that decreased lung perfusion with VA-ECMO may accelerate pulmonary vascular thrombosis in the presence of severe lung injury.

12To date, animal data, observational studies and previous randomized trials may give a physiologic rationale to promote ultra-protective ventilation during ECMO.

13The main objectives of MV during ECMO for patients with severe acute respiratory failure are summarized in Figure 1. However, multiple approaches to ventilation could be acceptable. By directly removing CO2 from the blood, ECMO enables lung-protective ventilation. Without ECMO, difficulty maintaining adequate alveolar ventilation is one limitation to the use of a protective ventilation strategy – exposing patients to potential side effects of subsequent hypercapnia, such as intracranial pressure elevation, pulmonary hypertension, depressed myocardial contractility and a reduction in renal blood flow.

14Using tidal volume <4 ml/kg PBW is thus recommended with ECMO and is often referred to imprecisely as lung rest or ultra-protective ventilation. The concept of ultra-protective MV was suggested and investigated in animal studies. Using a rat model of acid-induced lung injury, Frank and colleagues showed that a tidal volume reduction from 12 to 6 to 3 ml/kg, with the same level of PEEP (10 cmH2O), decreased pulmonary edema and lung injury, and increased protection of the alveolar epithelium. In addition, post-hoc analysis of the ARDS Network data in a multivariable logistic regression model showed that lower tidal volume assignment and lower plateau pressure quartile were significant predictors of lower mortality. Favorable outcome of patients with ARDS treated with a strong tidal volume reduction until 1.9 ml/kg PBW with ECMO and with ECCO2R have been reported. Terragni and colleagues used a system that predominately removed CO2 to reduce tidal volume <6 ml/kg PBW and observed a reduction of pulmonary cytokine concentration. However, survival benefit from ultra-protective lung ventilation was not seen in a recent multicenter randomized controlled trial. Bein and colleagues compared a very low tidal volume ventilation strategy (≈ 3 ml/kg PBW) combined with ECCO2R to lower tidal ventilation (≈ 6 ml/kg PBW) without the extracorporeal device in 79 patients with ARDS. The number of ventilator-free days at day 60 and the mortality rates were not significantly different between the two study groups. However, promising results were found in patients with severe hypoxemia with a lower number of ventilator-free days at 60 days in the control group. In addition, Pham and colleagues recently showed, in a cohort of 123 patients with influenza A(H1N1)-induced ARDS, that a higher plateau pressure on the first day of VV-ECMO for acute respiratory failure was significantly associated with ICU death (odds ratio = 1.33, 95% confidence interval = 1.14 to 1.59, P <0.01). It is worth noting that the ultra-protective ventilation strategy was associated with the use of high PEEP levels in all cases.

15Using a pressure control approach with tight limitation of the peak inspiratory pressure between 20 and 25 cmH2O has been suggested to be beneficial. Depending on the severity of the lung disease, ultra-protective ventilation with plateau pressure limitation may lead to apneic ventilation (that is, no tidal volume) for several days. This may be particularly evident with pediatric patients, and in some cases the reduction of the tidal volume to achieve limited ventilation pressure strategy is considered so important that the result is insufficient ventilation to maintain adequate oxygen delivery. In this case, a third venous ECMO cannula to increase ECMO blood flow may be utilized rather than increasing the inspiratory pressure, which may negate the beneficial effect of the ECMO. Despite its feasibility reported on animal studies, pediatric studies and in our daily adult practice, the long-term effect of apneic ventilation is unknown. A very low tidal volume results in dead space ventilation only. In our opinion, this must be combined with a high level of PEEP, to maintain convective ventilation for the elimination of alveolar nitrogen and avoid alveolar collapse.

16Although there are no large randomized studies focused on MV settings during ECMO in severe acute respiratory failure, it is reasonable, at this time, to advise an ultra-protective ventilation strategy with ECMO, based on a tidal volume reduction (that is, <4 ml/kg PBW) and on a plateau pressure reduction (that is, ≤25 cmH2O), provided lung recruitment with PEEP is sufficient.

17For patients without ARDS treated by VA-ECMO, lung function is often abnormal. Cardiogenic pulmonary edema, postoperative lung damage and thoracic compliance reduction are frequently present after cardiac surgery, and these patients are at risk of developing ARDS. Targeting lower tidal volumes (6 to 8 ml/kg PBW) appears to decrease the incidence of adverse outcome, even without ARDS, and would appear to be reasonable in this population, as would a reduction in the respiratory rate during periods of minimal pulmonary artery blood flow. In addition, CO2 removal by VA-ECMO might allow a better tolerance of low tidal volume with less discomfort and dyspnea, and therefore less sedation – but this is an area for further research.

18It is important to be aware that, despite the use of ECMO, decreasing tidal volume <4 ml/kg PBW may increase atelectasis and result in severe ventilation/perfusion mismatch unless PEEP is appropriately increased. Higher PEEP levels are essential – probably higher than suggested by the Extracorporeal Life Support Organization (ELSO) guidelines, which suggest a modest PEEP of 10 cmH2O – while taking into account the risk of alveolar overdistension and increased alveolar strain. In addition, higher PEEP levels, can also maintain convective ventilation for the elimination of alveolar nitrogen accumulated during apneic oxygenation with ECMO.

19High PEEP levels may have an adverse effect on hemodynamics when the patient is managed in the VV-ECMO mode by inhibiting venous return. Although heart function is partially or completely replaced by VA-ECMO, high PEEP levels might also exacerbate right ventricular dysfunction and delay heart recovery. Particular caution and frequent cardiac echography monitoring should thus be advised for patients with ARDS and moderate right failure treated with VV-ECMO.

20To limit pulmonary oxygen toxicity, the ventilator fraction of inspired oxygen should also be reduced to the minimal value to keep arterial saturation >85%. Settings for the respiratory rate are debated, with some authors suggesting that rapid respiratory rates may increase mechanical lung stress. Current expert opinions vary, and a broad range has been suggested from 4 to 30 cycles/minute (Table 1). In our opinion, the respiratory rate must be set to maintain pH and arterial CO2 partial pressure within normal ranges. A first approach could thus be to tailor the respiratory rate to the tidal volume and ECMO gas flow settings.

21To date no study has compared different modes of MV during ECMO. The choice of mode used during ECMO must thus be guided by both physician usage pattern and local resource availability. However, an ultra-protective strategy should be advocated (Table 1).

22The assist-controlled mode in pressure or volume seems to be commonly used during the initial phase of ARDS with ECMO, when patients are often deeply sedated and paralyzed and when alterations of lung compliance are greatest. With the target settings discussed previously, the pressure-controlled mode appears to be advocated, and is probably the most popular mode in the initial phase of ARDS with ECMO. While minimizing the potential for VILI with ultra-protective ventilation, the pressure-controlled mode allows daily monitoring of the tidal volume increase as the patient’s condition improves. As the lung compliance improves, it is possible to see the gradual increase in tidal volume from very negligible tidal volume (50 ml) to 6 ml/kg PBW (inferior limit for ECMO weaning). However, while pressure control ventilation is advocated, some authors have recommended including spontaneous breathing to allow diaphragm contraction. Spontaneous breathing in any phase of the mechanical ventilator cycle is possible during airway pressure release ventilation, a ventilation mode that periodically switches between two levels of continuous positive airway pressure. Combined with spontaneous breathing, airway pressure release ventilation appeared to augment the distribution of ventilation to dependent lung regions, to decrease the workload on the respiratory muscle and to increase systemic blood flow in patients with severe ARDS. As a result, airway pressure release ventilation might be an alternative mode to conventional pressure-controlled MV in ARDS with ECMO.

23Prolonged controlled ventilation without diaphragmatic contraction may result in severe atrophy and increased duration of ventilatory support. The pressure-assisted mode with spontaneous diaphragm contraction should therefore be used as soon as possible. Recent case reports have noticed the successful combination of neurally adjusted ventilatory assist and ECMO in patients with severely impaired lung function in the recovery phase. The automated protective ventilation permitted with this closed-loop ventilation mode may improve patient–ventilator synchrony, particularly in patients with ARDS.

24In the case of patients with hypercapnic respiratory failure due to chronic obstructive pulmonary disease, or chronic end-stage respiratory failure treated with VV-ECMO or ECCO2R, the findings of recent pilot studies have suggested that the optimal management is to wean from MV as soon as possible once ECMO has been established. In this case, ECMO without invasive MV, named awake ECMO, seems feasible, is relevant and has been associated with good results.

25To obtain high-flow ECMO sufficient to perform ultra-protective ventilation, ECMO cannulas with high diameter are essential. Similarly, diuresis to dry weight and restrictive transfusion strategies should be attempted early in the patient’s management, despite volume expansion that may be needed at the initial phase of the disease. Every effort should then be made to achieve net negative fluid balance. In addition, tracheotomy is frequently done safely under ECMO in this population exposed to prolonged MV. Sedation and analgesia should be titrated as low as possible to conciliate protective ventilation with comfort and tolerance of the cannula.

26Many retrospective studies of patients with ARDS mechanically ventilated during ECMO did not provide details of MV settings. Table 1 summarizes the views of experts in the field in the form of the ELSO guidelines, MV network and protocols from previous or ongoing prospective randomized trials. For brief MV management, ELSO recommends ‘reasonable initial ventilator settings during extracorporeal life support (ECLS) … with a respiratory frequency of 4 to 5 per minute, modest PEEP (e.g. 10 cm H2O), and low inflation pressure (e.g. 10 cm H2O above PEEP, or a peak inspiratory pressure (PIP) of 20 cm H2O. Once patients are stabilized and sedation can be lightened, spontaneous ventilation with pressure support ventilation can be considered’.

27Despite current use of heterogeneous modes of MV, an ultra-protective ventilation strategy for ECMO with acute respiratory failure is commonly suggested as best practice (Table 1). To what extent we should reduce both the tidal volume and the plateau pressure to allow lung rest remains unknown and is an area for future research. Similarly, the impact of PEEP and tidal volume on the timing of recovery of heart function in patients supported with VA-ECMO is unclear and is another important area of future research.

28Recent publications have suggested several directions forward.

29In the future, will we still need invasive MV with ECMO at all? As described previously, invasive MV is a potential cause of VILI and ventilator-associated pneumonia, which can further enhance the initial lung damage. Numerous centers have reported the strategy of employing ECMO as a bridge to lung transplantation without invasive ventilation.

30A recent pilot study has suggested that ECMO might be used for hypercapnic respiratory failure in chronic obstructive pulmonary disease patients as an alternative to non-invasive ventilation or in the case of non-invasive ventilation failure. In a proof-of-concept study, 26 patients awaiting lung transplantation who developed end-stage respiratory failure and were supported with ECMO while awake (that is, no invasive ventilation) were retrospectively compared with a historical control group. The control group was supported with invasive MV as a bridge to lung transplantation. Despite the same duration of assistance, the 6-month survival after transplantation was higher in the ECMO group. The main benefits of awake ECMO were avoiding the complications of prolonged intubation, MV and sedation, as well as maintaining active physical activity while receiving ECMO, which may have improved physical fitness prior to transplantation. The same strategy was also described as feasible and safe with VA-ECMO. This is briefly suggested by the ELSO guidelines as: ‘… An alternative is to extubate the patient and allow spontaneous breathing with the patient awake’.

31Recent advances in ECMO technology and a better understanding of the respiratory drive, in particular the source of dyspnea and discomfort, might allow the use of ECMO as an alternative to invasive MV in selected patients with ARDS. Hoeper and colleagues recently reported the feasibility of VV-ECMO in six awake, non-intubated, spontaneously breathing patients with ARDS. Avoiding mechanical ventilation might be of particular interest in specific patient populations that are placed at high risk with invasive ventilation; for example, patients with immunosuppression or end-stage chronic lung disease.

32Description of actual MV management with ECMO worldwide is warranted to give the basis to design future interventional trials. For instance, evaluation of the impact of an ultra-protective lung ventilation strategy with ECMO for ARDS by a large international randomized trial is now needed.

33As blood gas is a mix up of oxygen delivered both from the ECMO and from the native lung, monitoring the native lung during ECMO is very scanty. However, simple beside tools are available. Daily plateau pressure and compliance monitoring is a first, but imperfect, way to monitor native lung function. In addition, if a pressure mode is used, the daily monitoring of the tidal volume obtained may be valuable information. Although there is no published evidence, continuous measurement of end-tidal CO2 is used by some teams to monitor native lung improvement during the ECMO course. Moreover, MV during ECMO may lead to overdistension and under-recruitment depending on the degree of heterogeneity of regional compliance.

34Assessment of regional lung mechanics is not easy with extremely severe ARDS prior to or during ECMO. Therefore, for technical and safety reasons, thoracic computed tomography could not be routinely recommended for these patients. Electrical impedance tomography could be considered as a MV monitoring tool prior and during ECMO for ARDS. Some authors have suggested that it could be a bedside tool to identify patients in whom lung protection and reversal of hypoxemia is not achievable with MV (that is, ECMO recipient), or to identify patients who would benefit from MV with lung recruitment maneuvers (that is, ECMO nonrecipient). Similarly, Grasso and colleagues suggested the use of transpulmonary pressure (assessed by esophageal balloon) as a bedside tool to assess physiological titration of PEEP. Indeed, the authors demonstrated that 50% of patients with influenza A(H1N1)-associated ARDS referred to their unit for ECMO did not receive ECMO, because the transpulmonary pressure was lower than airway pressure alone. This unexpected lower value, mainly due to low chest wall compliance, allowed a safe increase in the PEEP level, which in turn increased oxygenation and avoided the use of ECMO. This individually tailored approach could be the future direction of research to select the ‘best’ candidates for ECMO, if used as a rescue therapy for severe acute hypoxemic respiratory failure.

35Although the positive impact of a protective lung ventilation strategy on survival in ARDS has been clearly demonstrated, in patients receiving MV during ECMO there is limited evidence to guide practice. Based on actual and past randomized trials of ARDS with ECMO, an ultra-protective ventilation strategy that limits tidal volume to <4 ml/kg PBW, targets a very low plateau pressure (<25 cmH2O) and is supported by increased alveolar recruitment with PEEP may be the best option for clinicians managing these critically ill patients. As the use of ECMO increases internationally, future studies are urgently required to determine the best practice of MV during ECMO and its impact on patient-centered outcomes.

36ARDS: Adult respiratory distress syndrome; CO2: Carbon dioxide; ECCO2R: Extracorporeal carbon dioxide removal; ECMO: Extracorporeal membrane oxygenation; ELSO: Extracorporeal Life Support Organization; MV: Mechanical ventilation; PBW: Predicted body weight; PEEP: Positive end-expiratory pressure; VA-ECMO: Venoarterial extracorporeal membrane oxygenation; VILI: Ventilator-induced lung injury; VV-ECMO: Venovenous extracorporeal membrane oxygenation.

37AC is the primary investigator of the EOLIA trial, NCT01470703, a randomized trial of VV-ECMO supported in part by MAQUET. AC has received honoraria for lectures from MAQUET. The remaining authors declare that they have no competing interests.